MA35086B1 - Compose de triazolopyridine - Google Patents
Compose de triazolopyridineInfo
- Publication number
- MA35086B1 MA35086B1 MA36027A MA36027A MA35086B1 MA 35086 B1 MA35086 B1 MA 35086B1 MA 36027 A MA36027 A MA 36027A MA 36027 A MA36027 A MA 36027A MA 35086 B1 MA35086 B1 MA 35086B1
- Authority
- MA
- Morocco
- Prior art keywords
- triazolopyridine
- compound
- formula
- relates
- triazolopyridine compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 title 1
- 150000008523 triazolopyridines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
L'invention concerne des composés de triazolopyridine de formule (i), dans laquelle r
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10194014 | 2010-12-07 | ||
| PCT/EP2011/071685 WO2012076430A1 (fr) | 2010-12-07 | 2011-12-05 | Composés de triazolopyridine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35086B1 true MA35086B1 (fr) | 2014-05-02 |
Family
ID=45099086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36027A MA35086B1 (fr) | 2010-12-07 | 2013-06-20 | Compose de triazolopyridine |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8349824B2 (fr) |
| EP (1) | EP2649070B1 (fr) |
| JP (1) | JP5932828B2 (fr) |
| KR (1) | KR20130128426A (fr) |
| CN (1) | CN103237803B (fr) |
| AR (1) | AR084152A1 (fr) |
| AU (1) | AU2011340685A1 (fr) |
| BR (1) | BR112013013912A2 (fr) |
| CA (1) | CA2816829C (fr) |
| CL (1) | CL2013001591A1 (fr) |
| CO (1) | CO6741154A2 (fr) |
| CR (1) | CR20130239A (fr) |
| CY (1) | CY1115863T1 (fr) |
| DK (1) | DK2649070T3 (fr) |
| EA (1) | EA022607B1 (fr) |
| EC (1) | ECSP13012667A (fr) |
| ES (1) | ES2520647T3 (fr) |
| HR (1) | HRP20141200T1 (fr) |
| IL (1) | IL225969A0 (fr) |
| MA (1) | MA35086B1 (fr) |
| MX (1) | MX2013006054A (fr) |
| PE (1) | PE20140226A1 (fr) |
| PH (1) | PH12013500942A1 (fr) |
| PL (1) | PL2649070T3 (fr) |
| PT (1) | PT2649070E (fr) |
| RS (1) | RS53677B1 (fr) |
| SG (1) | SG190305A1 (fr) |
| SI (1) | SI2649070T1 (fr) |
| UA (1) | UA109037C2 (fr) |
| WO (1) | WO2012076430A1 (fr) |
| ZA (1) | ZA201303811B (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013043518A1 (fr) | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Composés imidazopyridyliques utilisables en tant qu'inhibiteurs de l'aldostérone synthase |
| US9193724B2 (en) | 2011-09-22 | 2015-11-24 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
| EP2812330B1 (fr) | 2012-02-09 | 2015-12-02 | F.Hoffmann-La Roche Ag | Procédé de préparation de dérivés de 2-phényl-[1,2,4]triazolo[1,5-a]pyridine |
| BR112015017674A2 (pt) * | 2013-01-31 | 2017-07-11 | Hoffmann La Roche | compostos rádio marcados |
| KR102169426B1 (ko) | 2013-02-27 | 2020-10-23 | 모찌다 세이야쿠 가부시끼가이샤 | 신규 피라졸 유도체 |
| JP2016520047A (ja) | 2013-04-30 | 2016-07-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ピラゾールアミドのＰｄ触媒カップリング |
| MY172600A (en) * | 2013-05-31 | 2019-12-05 | Nissan Chemical Ind Ltd | Heterocyclic amide compound |
| WO2015006689A1 (fr) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Traitement et diagnostic du cancer et d'états précancéreux à l'aide d'inhibiteurs de pde10a et procédés pour mesurer l'expression de pde10a |
| CN107074844A (zh) * | 2014-07-30 | 2017-08-18 | 持田制药株式会社 | 吡唑衍生物的制造方法 |
| WO2016017711A1 (fr) * | 2014-07-30 | 2016-02-04 | 持田製薬株式会社 | Procédé de fabrication d'un dérivé de pyrazole |
| JP6745594B2 (ja) * | 2015-11-26 | 2020-08-26 | 持田製薬株式会社 | ピラゾール誘導体の塩の結晶 |
| WO2020021024A1 (fr) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Composés bicycliques substitués en tant que modulateurs du récepteur d'hydrocarbures aryle (ahr) |
| US12544364B2 (en) | 2020-06-05 | 2026-02-10 | Noema Pharma Ag | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome |
| CN121891333A (zh) * | 2020-06-05 | 2026-04-21 | 诺埃玛制药公司 | 用于治疗杜尔雷斯综合征的磷酸二酯酶10抑制剂的用途 |
| KR20230171918A (ko) | 2021-01-28 | 2023-12-21 | 노에마 파르마 아게 | 소아-발병 유창성 장애의 치료 방법 |
| WO2026068583A1 (fr) | 2024-09-25 | 2026-04-02 | Noema Pharma Ag | Utilisation de l'inhibiteur de phosphodiestérase 10 gemlapodect pour la perte de poids |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1651251A4 (fr) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
-
2011
- 2011-12-01 US US13/308,588 patent/US8349824B2/en active Active
- 2011-12-05 CA CA2816829A patent/CA2816829C/fr active Active
- 2011-12-05 PE PE2013001371A patent/PE20140226A1/es not_active Application Discontinuation
- 2011-12-05 EA EA201390799A patent/EA022607B1/ru not_active IP Right Cessation
- 2011-12-05 AR ARP110104533A patent/AR084152A1/es unknown
- 2011-12-05 JP JP2013542480A patent/JP5932828B2/ja active Active
- 2011-12-05 PT PT117915439T patent/PT2649070E/pt unknown
- 2011-12-05 DK DK11791543.9T patent/DK2649070T3/da active
- 2011-12-05 AU AU2011340685A patent/AU2011340685A1/en not_active Abandoned
- 2011-12-05 BR BR112013013912A patent/BR112013013912A2/pt not_active Application Discontinuation
- 2011-12-05 CN CN201180057674.XA patent/CN103237803B/zh active Active
- 2011-12-05 WO PCT/EP2011/071685 patent/WO2012076430A1/fr not_active Ceased
- 2011-12-05 MX MX2013006054A patent/MX2013006054A/es active IP Right Grant
- 2011-12-05 SI SI201130309T patent/SI2649070T1/sl unknown
- 2011-12-05 KR KR1020137016458A patent/KR20130128426A/ko not_active Ceased
- 2011-12-05 SG SG2013037676A patent/SG190305A1/en unknown
- 2011-12-05 PL PL11791543T patent/PL2649070T3/pl unknown
- 2011-12-05 PH PH1/2013/500942A patent/PH12013500942A1/en unknown
- 2011-12-05 ES ES11791543.9T patent/ES2520647T3/es active Active
- 2011-12-05 UA UAA201308329A patent/UA109037C2/uk unknown
- 2011-12-05 EP EP11791543.9A patent/EP2649070B1/fr active Active
- 2011-12-05 HR HRP20141200AT patent/HRP20141200T1/hr unknown
- 2011-12-05 RS RS20140574A patent/RS53677B1/sr unknown
-
2013
- 2013-04-25 IL IL225969A patent/IL225969A0/en unknown
- 2013-04-25 CO CO13105814A patent/CO6741154A2/es active IP Right Grant
- 2013-05-22 CR CR20130239A patent/CR20130239A/es unknown
- 2013-05-24 ZA ZA2013/03811A patent/ZA201303811B/en unknown
- 2013-06-04 CL CL2013001591A patent/CL2013001591A1/es unknown
- 2013-06-06 EC ECSP13012667 patent/ECSP13012667A/es unknown
- 2013-06-20 MA MA36027A patent/MA35086B1/fr unknown
-
2014
- 2014-11-14 CY CY20141100951T patent/CY1115863T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35086B1 (fr) | Compose de triazolopyridine | |
| MA35049B1 (fr) | Triazolopyridines | |
| MA35926B1 (fr) | Pyrrolidine-2-carboxamides substitués | |
| MA35089B1 (fr) | Inhibiteurs de la production de leucotrienes de type benzodioxane | |
| MA35664B1 (fr) | Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one | |
| MA37940A2 (fr) | Nouveaux dérivés bicycliques | |
| MA35357B1 (fr) | Composes de type anilines | |
| MA37519A1 (fr) | Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1 | |
| MA35245B1 (fr) | Pyridin-2-amides utiles comme agonistes de cb2 | |
| MA35452B1 (fr) | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante | |
| MA37142A3 (fr) | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine | |
| MA38645B1 (fr) | Nouveaux inhibiteurs de cyp17/antiandrogènes | |
| CR20120295A (es) | Triazolopiridinas | |
| MA34644B1 (fr) | Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2 | |
| CO6852084A2 (es) | Nuevos compuestos sustituidos con halógeno | |
| MX350892B (es) | Síntesis de compuesto antiviral. | |
| AU2011232516A8 (en) | Chemical compounds | |
| CR20130129A (es) | Anàlogos de buprenorfina | |
| MA34389B1 (fr) | Nouvelles aminopyrazoloquinazolines | |
| AU2014270524A8 (en) | 2-phenylimidazo [1,2-a]pyrimidines as imaging agents | |
| CR20120637A (es) | Triazolopiridinas sustituidas | |
| MA37686B1 (fr) | Composés phénoxyéthyl pipéridine | |
| UA107455C2 (uk) | Похідні індолу як протиракові агенти | |
| MX372721B (es) | Ánalogos halogenados de agentes antifi-broticos. | |
| CR20130041A (es) | ISOXAZOLO[5,4-b]PIRIDINAS HERBICIDAS |